Steel Craig, Korrelboom Kees, Fazil Baksh M, Kingdon David, Simon Judit, Wykes Til, Phiri Peter, van der Gaag Mark
Oxford Health NHS Foundation Trust, Oxford, UK; School of Psychology, University of Reading, UK.
Department of Anxiety Disorders, PsyQ Parnassia Group, Psychiatric Center, The Hague, the Netherlands; Department of Medical and Clinical Psychiatry, Tilburg University, Tilburg, the Netherlands.
Behav Res Ther. 2020 Dec;135:103734. doi: 10.1016/j.brat.2020.103734. Epub 2020 Sep 22.
Around half of people diagnosed with schizophrenia suffer from co-morbid depression, yet there are no evidence-based psychological treatments to target this presentation.
Participants were aged 18-65 years old, had a clinical diagnosis of schizophrenia or schizoaffective disorder and at least a mild level of depression. Participants were randomly assigned (1:1) to receive PoMeT or treatment as usual. PoMeT was delivered in up to 12 individual sessions within 3 months. We stratified randomisation by site and by severity of depression using randomised-permuted blocks. Assessments were carried out at baseline, 3-month, 6-month and 9-month by assessors who were blind to treatment allocation. The primary outcome was reduction in the symptoms of depression at 3-month, 6-month and 9-month as measured by the BDI-II. Analysis was by intention-to-treat with linear mixed-effects models. The trial was registered with the ISRCTN registry number 99485756.
One hundred participants were randomly assigned to either PoMeT (n = 49) or treatment as usual (n = 51). The reduction in BDI-II total score at 3 months was significantly greater for PoMeT than for treatment as usual (mean difference = 4.33, SE = 2.00, 95% CI 0.38 to 8.23; p = 0.03).
To our knowledge this is, to date, the largest powered randomised controlled trial focused on the psychological treatment of depression in people diagnosed with schizophrenia. Results indicate that a brief targeted intervention can reduce the symptoms of depression in the group. The main limitation of the study is the lack of an active control group which may contribute to an inflated treatment effect.
约半数被诊断为精神分裂症的患者患有共病性抑郁症,但目前尚无针对该症状的循证心理治疗方法。
参与者年龄在18至65岁之间,临床诊断为精神分裂症或分裂情感性障碍,且至少有轻度抑郁症状。参与者被随机分配(1:1)接受情绪管理与训练计划(PoMeT)或常规治疗。PoMeT在3个月内进行多达12次的个体治疗。我们采用随机排列区组按地点和抑郁严重程度进行分层随机化。评估由对治疗分配不知情的评估人员在基线、3个月、6个月和9个月时进行。主要结局是通过贝克抑郁量表第二版(BDI-II)测量的3个月、6个月和9个月时抑郁症状的减轻。分析采用意向性分析,使用线性混合效应模型。该试验已在国际标准随机对照试验编号注册库(ISRCTN registry)注册,注册号为99485756。
100名参与者被随机分配到PoMeT组(n = 49)或常规治疗组(n = 51)。3个月时,PoMeT组BDI-II总分的降低显著大于常规治疗组(平均差异 = 4.33,标准误 = 2.00,95%置信区间0.38至8.23;p = 0.03)。
据我们所知,这是迄今为止针对被诊断为精神分裂症患者的抑郁症心理治疗的最大规模随机对照试验。结果表明,一种简短针对性干预可减轻该组患者的抑郁症状。该研究的主要局限性是缺乏一个积极对照组,这可能导致治疗效果被夸大。